Patents Examined by Michael C. Henry
  • Fucoidan preparation, zinc-bound fucoidan and use thereof
    Patent number: 10822431
    Abstract: Provided is a technique for enhancing the absorption of fucoidan into the body and elevate various effects of fucoidan by using a fucoidan preparation that is characterized by containing fucoidan and zinc and the ratio of zinc to fucoidan being 0.005% or greater.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 3, 2020
    Assignee: South Product Ltd.
    Inventors: Takeaki Nagamine, Masahiko Iha, Kizuku Kadena
  • Edible composition
    Patent number: 10806744
    Abstract: Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. According to Node et al. (Cardiovascular diabetology, 8, 23 (2009)), repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: October 20, 2020
    Assignee: Conopco, Inc.
    Inventors: Mark Ian Fowler, Huijun Wang
  • Composition of novel carbohydrate drug for treatment of human diseases
    Patent number: 10799525
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 13, 2020
    Assignee: Galectin Therapeutics, Inc.
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Anti-viral formulations
    Patent number: 10786528
    Abstract: The present disclosure relates generally to the field of anti-viral therapy and prophylaxis. Formulations and agents are provided which inhibit viruses of the Orthomyxoviridae family and ameliorate symptoms and conditions caused by viral infection. The present disclosure teaches the control of influenza virus infection and spread and amelioration of conditions caused thereby. The formulations and agents may be processed as medicaments or as health supplements for more general application such as in the form of consumer goods or consumer foods.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: September 29, 2020
    Inventors: Helen Fitton, Vicki Gardiner
  • Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
    Patent number: 10780104
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: September 22, 2020
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Methods of treating breast cancer that overexpress AKT kinase
    Patent number: 10744148
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 18, 2020
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Graft copolymer
    Patent number: 10745493
    Abstract: A graft copolymer comprising: a core polymer comprising a crosslinked or non-crosslinked polysaccharide, a plurality of primary graft polymers covalently grafted to the core polymer, a plurality of secondary graft polymers covalently grafted to each primary graft polymer, an injectable dermal aesthetic formulation comprising such a graft copolymer and a method of preparing such a graft copolymer.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: August 18, 2020
    Assignee: GALDERMA S.A.
    Inventor: Kristoffer Bergman
  • Method of preparing cyclodextrin complexes
    Patent number: 10736967
    Abstract: Aspects of the disclosure feature a method that comprises preparing an agent-cyclodextrin complex. Preparing the agent-cyclodextrin complex includes contacting a first composition comprising an agent with a porous cyclodextrin-metal organic framework to form a second composition comprising an agent-cyclodextrin-metal organic framework complex, the cyclodextrin-metal organic framework including a plurality of cyclodextrin molecules and at least one metal cation. Preparing the agent-cyclodextrin complex also includes dissolving the agent-cyclodextrin-metal organic framework complex in an aqueous solvent to form a third composition including the agent-cyclodextrin complex.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: August 11, 2020
    Assignee: PanaceaNano, Inc.
    Inventors: Benjie N. Limketkai, Youssry Y. Botros
  • Ras inhibitors and uses thereof
    Patent number: 10723753
    Abstract: Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 28, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Sang Min Lim, Hwan Geun Choi, Kenneth Dale Westover, Matthew Meyerson
  • Noreugenin glycoside derivatives
    Patent number: 10722441
    Abstract: A use of noreugenin glycoside derivatives of formulas I, II and III as a self-tanning substance or to increase the synthesis of melanin, improve melanin transport and/or improve the distribution of melanin in suprabasal layers, preparations containing noreugenin glycoside derivatives of formulas I, II and III, and noreugenin glycoside derivatives of formulas I, II and III.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 28, 2020
    Assignee: Universitaet Hamburg
    Inventors: Christophe Carola, Michael Schulte, Ulrich Rabausch, Henning Rosenfeld, Wolfgang Streit
  • 5-azido-5-deoxy-2 :3-isopropylidene-D-arabinose compounds; their method of manufacture and their use for the synthesis of ARA-N3, KDO-N3 and 4EKDO-N3
    Patent number: 10717718
    Abstract: Disclosed are new compounds of formulae: Wherein: R1 and R2 can be independently H; a C1 to C6 alkyl including methyl, ethyl, propyl, butyl; aryl including phenyl, para-methoxyphenyl; or R1,R2 together with the carbon C-6 can be a cyclopentylidene or cyclohexylidene; each of these groups being substituted or not; and R3 can be a C1 to C6 alkyl including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl; or aryl including phenyl, methylphenyl, ethylphenyl, each of these groups being substituted or not. The invention also relates to their method of manufacture and their use for the synthesis of Ara-N3, Kdo-N3 and 4eKdo-N3.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: July 21, 2020
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Boris Vauzeilles, Jordi Mas Pons, Aurèlie Baron
  • Materials for treating and preventing mucosa related disease
    Patent number: 10709731
    Abstract: Provided is a hyaluronic acid (HA) composition for use in treating or preventing mucosa related disorders or diseases including a mixture of HAs having different average molecular weights and different rheological, isolation, tissue scaffold and degradation properties. The resulting formulation demonstrates an optimal balance between adhesion, tissue scaffold and treating time on the treatment and prevention of mucosa related disorders or diseases including conjunctivitis, otitis, allergic rhinitis, gingivitis, oral ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), urethritis, cystitis and vaginitis.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 14, 2020
    Assignee: AIHOL CORPORATION
    Inventor: Shyh-Shyan Lin
  • Compositions for use in stimulating bone growth
    Patent number: 10675290
    Abstract: The present invention relates to use of a composition for maintenance of bone and/or cartilage health or prevention, alleviation and/or treatment of bone and/or cartilage disorders.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: June 9, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Marie Noelle Horcajada, Fanny Membrez, Elizabeth Offord Cavin
  • Chondroitin complexes for transcutaneous absorption
    Patent number: 10675270
    Abstract: The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 9, 2020
    Assignee: Altergon S.A.
    Inventors: Mario De Rosa, Chiara Schiraldi
  • Sulfated-glycolipids as adjuvants for vaccines
    Patent number: 10647737
    Abstract: A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid:uncharged glycolipid) and which induce a protective immune response, including CD8+ and CD4+ T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: May 12, 2020
    Assignee: National Research Council of Canada
    Inventors: Dennis M. Whitfield, G. Dennis Sprott, Lakshmi Krishnan
  • Maltosyl-isomaltooligosaccharides
    Patent number: 10632141
    Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: April 28, 2020
    Assignee: ISOThrive Inc.
    Inventors: Lee Madsen, II, Jack Oswald
  • Antiviral supplement formulations
    Patent number: 10478447
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 19, 2019
    Assignee: Vymedic, LLC
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Resistant dextrin and method for preparing the same
    Patent number: 10479840
    Abstract: A resistant dextrin and a method for preparing the same. In the resistant dextrin, molar content of DP1 is smaller than or equal to 1%, molar content of DP2 is smaller than or equal to 4.5%, molar content of DP3 is smaller than or equal to 7.0%, an average degree of polymerization is 6-12, a pH value is 3.0-6.0, and molar content of dietary fibers is greater than or equal to 85%. The present invention further relates to a method for preparing the resistant dextrin. Since the present invention uses starch as the raw material and divides dextrinization reaction into two stages for the first time, the degree of polymerization of the polymerization reaction is reliably guaranteed, the number of caused side reactions is decreased at the same time and the difficulty in subsequent purification treatment is greatly decreased.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: November 19, 2019
    Assignee: SHANDONG BAILONG CHUANGYUAN BIO-TECH CO., LTD
    Inventors: Guangpeng Dou, Zhaobo Gan, Fanghua Li, Xianbao Shao, Tengteng Yang, Qian Du, Mingzhan Zhang, Xingjing Zhang
  • Polysaccharide suitable to modulate immune response
    Patent number: 10449249
    Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: October 22, 2019
    Assignee: NUTRILEADS B.V.
    Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
  • Material comprising outer layer having entanglement of hydrophobic polymer host blended with anhydride functionalized hydrophobic polymer co-host and hydrophilic guest
    Patent number: 10435523
    Abstract: The present disclosure provides, inter alia, a method of producing an outer layer material for forming into a structure and that comprises an entanglement having a hydrophobic polymer host and a hydrophilic guest, including in one embodiment the steps of: intermingling cloaked hydrophilic guest complexes with the hydrophobic host; crosslinking molecules of the guest with the guest; and performing a hydrolysis reaction.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: October 8, 2019
    Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Susan P. James, Min Zhang, Guy Beauregard, Rachael Kurkowski Oldinski